Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti –PD-1 therapy
Combination immunotherapy with nivolumab and ipilimumab has a high initial response rate in advanced melanoma; however, up to 55% of patients later progress. The efficacy and safety of ipilimumab re-induction in the setting of acquired resistance (AR) to combination immunotherapy is unknown.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Adriana Hepner, Victoria G. Atkinson, James Larkin, Rebecca A. Burrell, Matteo S. Carlino, Douglas B. Johnson, Lisa Zimmer, Katy K. Tsai, Oliver Klein, Serigne N. Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Ines Pires da Silva, Camille Gera Tags: Original Research Source Type: research